Levin is developing a unique proprietary line of medicinal cannabis products called “Levin TM”.

Levin is aimed at active and retired athletes suffering from a range of chronic pain indications, related to their sports activity.

Chronic pain is the largest target ailment globally for medicinal cannabis products, in some markets accounting for as much as 80% of prescriptions.

There is growing clinical evidence for the analgesic benefits of cannabis medicines, without the addiction problems associated with opioid painkillers.

Levin is based on a unique cannabinoid formulation developed for both its analgesic and anti-inflammatory properties.

Levin is preparing to undertake a world first clinical trial with a cohort of retired athletes, suffering from chronic pain as a result of their sports history.

Levin plans to increasingly target its medicinal cannabis products for specific patient cohorts and indications.